anti-TNBC agent-1 is a highly effective compound specifically targeting and combating triple-negative breast cancer (TNBC), demonstrating remarkable potency against various breast cancer cell types with IC50 values ranging from 0.20 μM to 0.27 μM. Its mechanism of action involves inducing apoptosis in SUM-159 cells through the mitochondria pathway and causing G1 phase arrest in these cells.

Anti-TNBC agent-1 (compound 7) demonstrates significant efficacy against a range of breast cancer cell lines, including MDA-MB231, SUM-159, MCF-7, Bcap-37, and 4T1. The compound achieves IC50 values between 0.20 µM to 0.27 µM, indicating a 11.6- to 18.6-fold enhancement in potency relative to its progenitor, parthenolide, which has IC50 values between 2.68 µM and 4.63 µM. Notably, anti-TNBC agent-1 surpasses the effectiveness of the benchmark drug Adriamycin (ADR)[1]. Specifically, at concentrations of 2 µM and 5 µM over 48 hours, it significantly increases apoptosis induction in SUM-159 cells compared to parthenolide[1], establishing its superior therapeutic potential. Moreover, anti-TNBC agent-1 exhibits selective cytotoxicity towards breast cancer cells, with an IC50 of 0.22 µM, as opposed to the negligible effect on 3T3 cells (IC50 = 8.13 µM)[1], underscoring its specificity and promising profile as a targeted anti-TNBC therapy.